» Articles » PMID: 33494411

Pathomechanism Characterization and Potential Therapeutics Identification for Parkinson's Disease Targeting Neuroinflammation

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2021 Jan 26
PMID 33494411
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the loss of dopaminergic (DAergic) neurons and the presence of α-synuclein-containing Lewy bodies. The unstructured α-synuclein forms insoluble fibrils and aggregates that result in increased reactive oxygen species (ROS) and cellular toxicity in PD. Neuroinflammation engaged by microglia actively contributes to the pathogenesis of PD. In this study, we showed that VB-037 (a quinoline compound), glycyrrhetic acid (a pentacyclic triterpenoid), inflata ( inflata, a Chinese herbal medicine), and Shaoyao Gancao Tang (SG-Tang, a formulated Chinese medicine) suppressed the nitric oxide (NO) production and interleukin (IL)-1β maturation in α-synuclein-stimulated BV-2 cells. Mouse inflammation antibody array further revealed increased IL-1α, IL-1β, tumor necrosis factor (TNF)-α, interferon (IFN)-γ, IL-6, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) expression in α-synuclein-inflamed BV-2 cells and compound pretreatment effectively reduced the expression and release of these pro-inflammatory mediators. The test compounds and herbal medicines further reduced α-synuclein aggregation and associated oxidative stress, and protected cells against α-synuclein-induced neurotoxicity by downregulating NLR family pyrin domain containing 1 (NLRP1) and 3 (NLRP3), caspase 1, IL-1β, IL-6, and associated nuclear factor (NF)-κB inhibitor alpha (IκBα)/NF-κB P65 subunit (P65), c-Jun N-terminal kinase (JNK)/proto-oncogene c-Jun (JUN), mitogen-activated protein kinase 14 (P38)/signal transducer and activator of transcription 1 (STAT1) and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) pathways in dopaminergic neurons derived from α-synuclein-expressing SH-SY5Y cells. Our findings indicate the potential of VB-037, glycyrrhetic acid, inflata, and SG-Tang through mitigating α-synuclein-stimulated neuroinflammation in PD, as new drug candidates for PD treatment.

Citing Articles

Oxidative stress and dysregulated long noncoding RNAs in the pathogenesis of Parkinson's disease.

Wang J, Liu M, Zhao J, Hu P, Gao L, Tian S Biol Res. 2025; 58(1):7.

PMID: 39871377 PMC: 11770960. DOI: 10.1186/s40659-025-00585-7.


Coumarin-chalcone derivatives as dual NLRP1 and NLRP3 inflammasome inhibitors targeting oxidative stress and inflammation in neurotoxin-induced HMC3 and BE(2)-M17 cell models of Parkinson's disease.

Lin T, Chiu Y, Lin C, Chen Y, Lin W, Wu Y Front Aging Neurosci. 2024; 16:1437138.

PMID: 39411284 PMC: 11473416. DOI: 10.3389/fnagi.2024.1437138.


Differentiation and regulation of CD4 T cell subsets in Parkinson's disease.

Sun X, Gu R, Bai J Cell Mol Life Sci. 2024; 81(1):352.

PMID: 39153043 PMC: 11335276. DOI: 10.1007/s00018-024-05402-0.


From inflammatory signaling to neuronal damage: Exploring NLR inflammasomes in ageing neurological disorders.

Zhang J, Xie D, Jiao D, Zhou S, Liu S, Ju Z Heliyon. 2024; 10(12):e32688.

PMID: 38975145 PMC: 11226848. DOI: 10.1016/j.heliyon.2024.e32688.


The Interaction Between Nutraceuticals and Gut Microbiota: a Novel Therapeutic Approach to Prevent and Treatment Parkinson's Disease.

Yao L, Yang Y, Yang X, Rezaei M Mol Neurobiol. 2024; 61(11):9078-9109.

PMID: 38587699 DOI: 10.1007/s12035-024-04151-2.


References
1.
McGeer P, Kawamata T, Walker D, Akiyama H, Tooyama I, McGeer E . Microglia in degenerative neurological disease. Glia. 1993; 7(1):84-92. DOI: 10.1002/glia.440070114. View

2.
Lee H, Lee K, Im H . α-Synuclein modulates neurite outgrowth by interacting with SPTBN1. Biochem Biophys Res Commun. 2012; 424(3):497-502. DOI: 10.1016/j.bbrc.2012.06.143. View

3.
Kaushal V, Dye R, Pakavathkumar P, Foveau B, Flores J, Hyman B . Neuronal NLRP1 inflammasome activation of Caspase-1 coordinately regulates inflammatory interleukin-1-beta production and axonal degeneration-associated Caspase-6 activation. Cell Death Differ. 2015; 22(10):1676-86. PMC: 4563782. DOI: 10.1038/cdd.2015.16. View

4.
Bassani T, Vital M, Rauh L . Neuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugs. Arq Neuropsiquiatr. 2015; 73(7):616-23. DOI: 10.1590/0004-282X20150057. View

5.
Xu X, Zhang L, Ye X, Hao Q, Zhang T, Cui G . Nrf2/ARE pathway inhibits ROS-induced NLRP3 inflammasome activation in BV2 cells after cerebral ischemia reperfusion. Inflamm Res. 2017; 67(1):57-65. DOI: 10.1007/s00011-017-1095-6. View